• 1
    Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med 2004;55:419432.
  • 2
    Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603625.
  • 3
    Horny HP, Akin C, Metcalfe DD et al. Mastocytosis (Mast cell disease). In: Swerdlow , SH , Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. editors. World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues, vol 2. Lyon, France: IARC Press, 2008: 5463.
  • 4
    Escribano L, Álvarez-Twose I, Sánchez-Muñoz L, Garcia-Montero A, Núñez R, Almeida J et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish network on mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009;124:514521.
  • 5
    Kors JW, Van Doormaal JJ, Breukelman H, Van Voorst Vader PC, De Monchy JG. Long-term follow-up of indolent mastocytosis in adults. J Intern Med 1996;239:157164.
  • 6
    Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003;122:695717.
  • 7
    Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RGl. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 1988;67:345368.
  • 8
    Barete S, Assous N, de Gennes C, Grandpeix C, Feger F, Palmerini F et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010;69:838841.
  • 9
    Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:11371148.
  • 10
    Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994;4:368381.
  • 11
    Donker ML, Van Doormaal JJ, Van Doormaal FF, Kluin PM, Van der Veer E, de Monchy J et al. Biochemical markers predictive for bone marrow involvement in systemic mastocytosis. Haematologica 2008;93:120135.
  • 12
    Granerus G, Lonnqvist B, Nystrand J, Roupe G. Serum tryptase measured with B12 and G5 antibody-based immunoassays in mastocytosis patients and its relation to histamine turnover. Br J Dermatol 1998;139:858861.
  • 13
    Keyzer JJ, Wolthers BG, Muskiet FA, Kauffman HF, Groen A. Determination of N tau-methylhistamine in plasma and urine by isotope dilution mass fragmentography. Clin Chim Acta 1981;113:165173.
  • 14
    Keyzer JJ, Wolthers BG, Breukelman H, Kauffman HF, de Monchy JG. Determination of N tau-methylimidazoleacetic acid (a histamine metabolite) in urine by gas chromatography using nitrogen-phosphorus detection. Clin Chim Acta 1982;121:379387.
  • 15
    Oosting E, Keyzer JJ, Wolthers BG, Scholtis RJ. Age dependent normal values of histamine and histamine metabolites in human urine. Agents Actions 1988;23:30710.
  • 16
    Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A et al. Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 2000;11:669674.
  • 17
    Van Staa TP, Dennison EM, Leufkens HGM, Cooper C. Epidemiology of fractures in England and Wales. Bone 2001;29:517522.
  • 18
    Ismail AA, Pye SR, Cockerill WC, Lunt M, Silman AJ, Reeve J et al. Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int 2002;13:565571.
  • 19
    Hedström EM, Svensson O, Bergström U, Michno P. Epidemiology of fractures in children and adolescents. Acta Orthop 2010;81:148153.
  • 20
    Cooper C, Dennison EM, Leufkens HG, Bishop N, van Staa TP. Epidemiology of childhood fractures in Britain: a study using the general practice research database. J Bone Miner Res 2004;19:19761981.
  • 21
    Alvarez-Twose I, González de Olano D, Sánchez-Muñoz L, Matito A, Esteban-López MI, Vega A et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol 2010;25:12691278.
  • 22
    Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:20102018.
  • 23
    Bergström U, Björnstig U, Stenlund H, Jonsson H, Svensson O. Fracture mechanisms and fracture pattern in men and women aged 50 years and older: a study of a 12-year population-based injury register, Umeå, Sweden. Osteoporos Int 2008;19:12671273.
  • 24
    Ebeling PR. Osteoporosis in men. N Engl J Med 2008;358:14741482.
  • 25
    Harvey N, Dennisson E, Cooper C. Epidemiology of osteoporotic fractures. In: Rosen CJ, Compston JE, Lian JB editors. Primer on the metabolic bone diseases and disorders of mineral metabolism, 7th edn. Washington DC: ASBMR, 2008: 198203.
  • 26
    Chen W, Beck I, Schober W, Brockow K, Effner R, Buters JT, et al. Human mast cells express androgen receptors but treatment with testosterone exerts no influence on IgE-independent mast cell degranulation elicited by neuromuscular blocking agents. Exp Dermatol 2010;19:302304.
  • 27
    Brumsen C, Papapoulos SE, Lentjes EG, Kluin PM, Hamdy NA. A potential role for the mast cell in the pathogenesis of idiopathic osteoporosis in men. Bone 2002;5:556561.
  • 28
    Chiapetta N, Gruber B. The role of mast cells in osteoporosis. Semin Arthritis Rheum 2006;36:3236.
  • 29
    Theoharides TC, Alysandratos KD, Angelidou A, Delivanis DA, Sismanopoulos N, Zhang B et al. Mast cells and inflammation. Biochim Biophys Acta 2012;1822:2133.
  • 30
    Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 2002;128:344350.
  • 31
    Brockow K, Akin C, Huber M, Metcalfe DD. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 2005;115:216223.
  • 32
    Kushnir-Sukhov NM, Brittain E, Reynolds JC, Akin C, Metcalfe DD. Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis. Int Arch Allergy Immunol 2006;139:265270.
  • 33
    Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009;113:57275736.
  • 34
    Sánchez-Muñoz L, Alvarez-Twose I, García-Montero AC, Teodosio C, Jara-Acevedo M, Pedreira CE et al. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol 2011;24:11571168.
  • 35
    Sánchez-Muñoz L, Teodósio C, Morgado JM, Escribano L. Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders. Methods Cell Biol 2011;103:333359.
  • 36
    Rossini M, Zanotti R, Bonadonna P, Artuso A, Caruso B, Schena D et al. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 2011;49:880885.